Showing 4201-4210 of 7172 results for "".
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- ASDS Announces On-demand Course for Dermatologists Planning to Take the New MDS Subspecialty Certification Examinationhttps://practicaldermatology.com/news/asds-announces-on-demand-course-for-dermatologists-planning-to-take-the-new-mds-subspecialty-certification-examination/2460598/To help board certified dermatologists prepare for the American Board of Dermatology’s (ABD) first ever Micrographic Dermatologic Surgery (MDS) Subspecialty Certification Examination next fall, the American Society for Dermatologic Surgery (ASDS) is offering the
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2
- EADV Congress Update: Insights on Psoriasis, AD, UV Protection, COVID-19, and Morehttps://practicaldermatology.com/news/eadv-congress-update-insights-on-psoriasis-ad-uv-protection-covid-19-and-more/2460588/From updates on investigational treatments for dermatologic diseases to emerging healthcare trends, data from the 29th EADV Congress, EADV Virtual suggest new directions in patient care. Psoriasis: Results from the phas
- Coping with COVID-19: ‘Long-hauler’ COVID-19 Patients Experience Prolonged Skin Symptomshttps://practicaldermatology.com/news/coping-with-covid-19-long-hauler-covid-19-patients-experience-prolonged-skin-symptoms/2460584/Some COVID-19 patients experience long-lasting skin symptoms that vary according to type of COVID-19 skin rash, according to a late-breaking abstract presented at the 29th EADV Congress, EADV Virtual. The analysis of the largest registry of COVID-19 patients with dermatological sym
- Dermatologist Named AAD Patient Hero for Providing Skin Care to People Experiencing Homelessness Amid COVID-19https://practicaldermatology.com/news/dermatologist-names-aad-patient-hero-for-providing-skin-care-to-people-experiencing-homelessness-amid-covid-19/2460582/Jennifer Tan, MD, FAAD is an American Academy of Dermatology (AAD) Patient Care Hero for making critical skin care and hygiene items easily accessible to individuals experiencing homelessness during the COVID-19 pandemic. As the state government issued COVID-19 stay-at-home guidanc
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).